July 2019
Volume 60, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2019
Stanniocalcin-1, a downsteam effector molecule in latanoprost signaling, does not signal through the FP receptor for IOP reduction
Author Affiliations & Notes
  • Gavin Roddy
    Mayo Clinic, Pine Island, Minnesota, United States
  • Michael P Fautsch
    Mayo Clinic, Pine Island, Minnesota, United States
  • Footnotes
    Commercial Relationships   Gavin Roddy, None; Michael Fautsch, None
  • Footnotes
    Support  Mayo Foundation
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 3783. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Gavin Roddy, Michael P Fautsch; Stanniocalcin-1, a downsteam effector molecule in latanoprost signaling, does not signal through the FP receptor for IOP reduction. Invest. Ophthalmol. Vis. Sci. 2019;60(9):3783.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose : We recently identified Stanniocalcin-1 (STC-1) as a downstream effector molecule in latanoprost signaling that was both necessary and sufficient for IOP reduction. However, it was unknown whether STC-1 and latanoprost had equivalent IOP reduction, whether the two agents were additive for IOP reduction, and if they signaled through the same cellular receptor. In the current study, we compared IOP reduction with STC-1, latanoprost, and the combination of the two agents. We additionally tested whether STC-1 signaled through the cellular receptor of latanoprost, the Prostaglandin F (FP receptor), by pharmacologically blocking the FP receptor.

Methods : C57B6J mice were treated for 5 days with daily topical application of 5 µL of one of the following treatment regimens: latanoprost-free acid (LFA; 100 µM dissolved in 1:1000 DMSO in PBS) alone, STC-1 (0.5mg/ml; Biovender Research and Diagnostic Products (Czech Republic) alone, FP receptor inhibitor AL-8810 (10mM) alone, LFA + STC-1, LFA + AL-8810, or STC-1 + AL-8810. In all cases, the contralateral eye was treated with vehicle. IOP was accessed using a handheld rebound tonometer in conscious mice during the treatment period which included 3 days of pre-treatment baseline IOP and a 3-day washout period. For purposes of statistical analysis, IOP at the treatment nadir (day 4) was used.

Results : IOP was significantly reduced compared to vehicle control in LFA (n=6; 20.1%, P = 0.002), STC-1 (n=6, 18.7%, P<0.00001), LFA + STC-1 (n=6, 17.6%, P=0.002) treated animals. There was no significant difference when comparing treatment groups to one another. Compared to vehicle control, there was no significant difference in IOP in animals treated with AL-8810 alone or with AL-8810 + LFA. However, animals treated with AL-8810 + STC-1 demonstrated a significant IOP reduction (n=6, 22.7%, P=0.005).

Conclusions : STC-1 may be a novel therapy with equivalent IOP reduction as LFA that does not require signaling through the FP receptor. This may have important implications for patients that are unresponsive to latanoprost therapy

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.